SUNDRA DAVIS: Open Payments
NPI 1760098321 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$258 in 13 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $14 · 2025 $258
Food & beverage: $258
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $53 |
| Amgen Inc. | 3 | $53 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| PFIZER INC. | 1 | $24 |
| ABBVIE INC. | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
Products named: OTEZLA, Kerendia, Ozempic, PREVNAR 20, QULIPTA, FARXIGA, Wegovy, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
